8-K: Aardvark Therapeutics Updates Pipeline, Funding to 2027

Aardvark Therapeutics, Inc. updated its corporate presentation, highlighting pipeline advancements in rare metabolic diseases and obesity, with funding secured into 2027 and key data readouts anticipated.

Summary

• Aardvark Therapeutics, Inc. updated its corporate presentation for investors and analysts on September 2, 2025.
• The company is focused on suppressing hunger to treat rare metabolic diseases, specifically hyperphagia in Prader-Willi Syndrome (PWS), and the obesity epidemic.
• The balance sheet is funded into 2027, supporting ongoing and planned developments.
• Topline data for the Phase 3 HERO trial for ARD-101 in PWS is expected in Q3 2026.
• ARD-101, an oral drug, targets the root cause of hunger by activating gut-localized hormone secretion, including CCK.
• The PWS market opportunity is estimated at >$4.6 billion annually in the U.S., with the only currently approved therapy priced at >$450,000 per year.
• In Phase 2 trials, ARD-101 showed an average 8.5-point decrease in the HQ-CT 9 score in 28 days and was well-tolerated.
• ARD-201, a fixed-dose combination of a TAS2R agonist and a DPP-4 inhibitor, is being developed for obesity.
• Preclinical data for ARD-201 demonstrated approximately 19% weight loss in 30 days in a diet-induced obesity mouse model.
• ARD-201 also prevented weight regain and enhanced GLP-1RA efficacy, leading to approximately 30% weight loss when combined with tirzepatide in preclinical models.
• Phase 2 POWER trial for ARD-201 (weight maintenance post-GLP-1RA) is expected to initiate in 2H 2025.
• Phase 2 STRENGTH trial for ARD-201 (weight loss, combination with GLP-1RA) is expected to initiate in 1H 2026.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook, highlighting significant progress in clinical development for ARD-101, promising preclinical data for ARD-201, and a clear strategic path for addressing large unmet medical needs. The company's balance sheet is funded into 2027, providing stability. The potential to address limitations of existing therapies in both PWS and obesity markets contributes to a highly favorable sentiment.

Positives

• Balance sheet funded into 2027, providing financial stability for ongoing development.
• Positive Phase 2 clinical data for ARD-101 in Prader-Willi Syndrome, showing an 8.5-point decrease in HQ-CT 9 score in 28 days and good tolerability.
• Significant market opportunity in Prader-Willi Syndrome, with an estimated >$4.6 billion annual U.S. market.
• Promising preclinical data for ARD-201 in obesity, demonstrating ~19% weight loss and preventing weight regain.
• ARD-201 showed enhanced efficacy when combined with tirzepatide in preclinical models, achieving ~30% weight loss.
• Advancing a multi-indication pipeline with two distinct drug candidates addressing large unmet medical needs.
• Experienced leadership team with a track record in drug approvals and commercialization.

Risks

• Forward-looking statements and projections are subject to significant business, economic, and competitive uncertainties and contingencies, many beyond the company's control.
• Actual results may vary materially from projected results.
• The company undertakes no obligation to update or revise any forward-looking statements.
• Products are under clinical investigation and not yet approved for marketing by the U.S. Food and Drug Administration, with no representation made as to safety or effectiveness.
• Clinical trials may not achieve primary endpoints or demonstrate sufficient efficacy or safety for regulatory approval.
• Competition from existing therapies (e.g., VYKAT XR for PWS, GLP-1RAs for obesity) and other pipeline candidates.
• Potential for adverse reactions or safety issues in ongoing or future clinical trials.
• Market adoption and payer access for new therapies may be challenging even with approval.

Future Outlook

Aardvark Therapeutics anticipates topline data from its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome in Q3 2026. The company plans to initiate the Phase 2 POWER trial for ARD-201 in weight maintenance in the second half of 2025 and the Phase 2 STRENGTH trial for ARD-201 in weight loss in the first half of 2026. The balance sheet is funded into 2027, supporting these development timelines.

Management Comments

• Positioned for Execution & Growth.
• Suppressing Hunger to Treat Rare Metabolic Diseases and Obesity.
• Goal to address limitations of existing therapies.
• Validated Market Opportunities: Populations with severe unmet medical needs.
• Novel Mechanism: Oral drug targeting root cause of hunger.
• Expert Leadership: Spans Clinical, Scientific, & Commercial.

Industry Context

The filing highlights Aardvark Therapeutics' strategic positioning in two high-growth and high-unmet-need areas: rare metabolic diseases, specifically Prader-Willi Syndrome (PWS), and the broader obesity market. In PWS, the company aims to offer an improved alternative to the currently approved therapy, VYKAT XR, which has significant limitations. In obesity, Aardvark is targeting the rapidly expanding GLP-1RA market, estimated to reach nearly $49 billion by 2030, by developing ARD-201 to address key limitations of existing GLP-1RA therapies, such as long-term compliance, gastrointestinal side effects, and weight regain post-discontinuation. The company seeks to differentiate its approach by targeting the root cause of hunger and offering solutions for weight maintenance and enhanced weight loss, potentially complementing or replacing current GLP-1RA treatments.

Comparison to Industry Standards

• ARD-101 for PWS aims to improve upon the currently approved VYKAT XR (Diazoxide Extended Release), which has renal and hepatic restrictions (not recommended in ~20% of adults with PWS), safety risks (hyperglycemia, ketoacidosis, affecting ~10-25% of PWS patients with T2D), and adverse reactions (36% hypertrichosis, 27% edema). ARD-101's Phase 2 data showed an 8.5-point HQ-CT 9 decrease in 28 days, compared to Soleno's DCCR Phase 3 data which required ~6 months to reach a 7-point clinically meaningful HQ-CT threshold.
• ARD-201 for obesity is positioned to address limitations of GLP-1RA therapies like Semaglutide and Tirzepatide, where ~50% of patients discontinue within 3 months, and ~2/3 of weight loss is regained within one year of withdrawal. Preclinical data showed ARD-201 induced ~19% weight loss in 30 days in a DIO-B6 mouse model, and when combined with tirzepatide, it exceeded the effect of tirzepatide alone, achieving ~30% weight loss. ARD-201 also prevented weight rebound, offering a potential maintenance-phase solution or an alternative for patients intolerant or unresponsive to GLP-1RAs.

Stakeholder Impact

• Shareholders: Potential for significant value creation through advancement of a de-risked, multi-indication pipeline addressing large market opportunities, supported by funding into 2027.
• Patients (Prader-Willi Syndrome): Potential for a novel, oral treatment (ARD-101) that targets the root cause of hyperphagia, offering an improved alternative to existing therapies with fewer side effects and earlier onset of benefit.
• Patients (Obesity): Potential for new, effective alternatives (ARD-201) that address limitations of current GLP-1RA therapies, offering improved safety, tolerability, and durable weight control.
• Healthcare Providers: New therapeutic options for challenging conditions like PWS and obesity, potentially improving patient outcomes and management strategies.

Next Steps

• Topline data readout for Phase 3 HERO trial (ARD-101 in PWS) expected Q3 2026.
• Initiation of Phase 2 POWER trial (ARD-201 for weight maintenance) expected 2H 2025.
• Initiation of Phase 2 STRENGTH trial (ARD-201 for weight loss) expected 1H 2026.

Key Dates

Recommendation

The filing presents a compelling investment case for Aardvark Therapeutics, driven by a robust and de-risked multi-indication pipeline targeting significant unmet medical needs in Prader-Willi Syndrome and obesity. Positive Phase 2 clinical data for ARD-101 and strong preclinical data for ARD-201, demonstrating superior or complementary profiles to existing treatments, suggest high therapeutic potential. The company's financial runway into 2027 provides stability for upcoming key milestones, including Phase 3 data readout in Q3 2026 and two Phase 2 initiations in 2025/2026. Given the large market opportunities, differentiated mechanisms of action, and experienced leadership, the stock represents a strong buy for investors with a long-term horizon and an appetite for biotechnology growth.

Keywords

Aardvark Therapeutics, Prader-Willi Syndrome, Obesity, Hyperphagia, ARD-101, ARD-201, TAS2R agonist, DPP-4 inhibitor, Clinical Trials, Phase 3, Rare Metabolic Diseases, Drug Development, Biotechnology, SEC Filing, Corporate Presentation